Assembly Biosciences Doses First Two Participants in Phase 2 Trial of Hepatitis Delta Drug ABI-6250

Bitget2026/10/29 20:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Assembly Biosciences dosed the first two participants in a Phase 2 trial of oral ABI-6250 for chronic hepatitis delta virus infection.
The trial targets approximately 80 participants, testing two once-daily doses for safety and antiviral activity.
Initial Phase 2 data are expected in the fourth quarter of 2027.
Phase 1a results supported further development, with a mean half-life of approximately four days supporting once-daily dosing.
Gilead holds an exclusive licensing option for ABI-6250 for $90 million through Phase 2 completion and review of the option data package.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291600PRIMZONEFULLFEED9856448) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Assembly Biosciences Doses First Two Participants in Phase 2 Trial of Hepatitis Delta Drug ABI-6250

You may also like

Crypto prices